Home › Research › Down syndrome and Alzheimer's
Cerebrovascular disease drives Alzheimer plasma biomarker concentrations in adults with Down syndrome
Edwards NC, Lao PJ, Alshikho MJ, Ericsson OM, Rizvi B, Petersen ME, O’Bryant S, Flores-Aguilar L et al.. medRxiv, 2023-11-29
Topic: Amyloid, tau and blood-test diagnosis
Importance By age 40 years over 90% of adults with Down syndrome (DS) have Alzheimer’s disease (AD) pathology and most progress to dementia. Despite having few systemic vascular risk factors, individuals with DS have elevated cerebrovascular disease (CVD) markers that track with the clinical progression of AD, suggesting a role for CVD that is hypothesized to be mediated by inflammatory factors. Objective To examine the pathways through which small vessel CVD contributes to AD-related pathophysiology and neurodegeneration in adults with DS.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Edwards, N. C., Lao, P. J., Alshikho, M. J., Ericsson, O. M., Rizvi, B., Petersen, M. E., et al. (2023). Cerebrovascular disease drives Alzheimer plasma biomarker concentrations in adults with Down syndrome. medRxiv. https://doi.org/10.1101/2023.11.28.23298693
Vancouver
Edwards NC, Lao PJ, Alshikho MJ, Ericsson OM, Rizvi B, Petersen ME, et al. Cerebrovascular disease drives Alzheimer plasma biomarker concentrations in adults with Down syndrome. medRxiv. 2023. doi:10.1101/2023.11.28.23298693.
BibTeX
@article{edwards2023-e40cb7d2,
author = {Edwards, N. C. and Lao, P. J. and Alshikho, M. J. and Ericsson, O. M. and Rizvi, B. and Petersen, M. E. and O’Bryant, S. and Flores-Aguilar, L. and others},
title = {{Cerebrovascular disease drives Alzheimer plasma biomarker concentrations in adults with Down syndrome}},
journal = {medRxiv},
year = {2023},
doi = {10.1101/2023.11.28.23298693},
url = {https://doi.org/10.1101/2023.11.28.23298693}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Despite having few systemic vascular risk factors, individuals with DS have elevated cerebrovascular disease (CVD) markers that track with the clinical progression of AD, suggesting a role for CVD that is hypothesized to be mediated by inflammatory factors.
- Objective To examine the pathways through which small vessel CVD contributes to AD-related pathophysiology and neurodegeneration in adults with DS.
- Design Cross sectional analysis of neuroimaging, plasma, and clinical data.
- Setting Participants were enrolled in Alzheimer’s Biomarker Consortium – Down Syndrome (ABC-DS), a multisite study of AD in adults with DS.
Why it matters
This cross-sectional analysis examined how small vessel cerebrovascular disease relates to Alzheimer's-related brain changes and neurodegeneration in adults with Down syndrome. It suggests cerebrovascular disease may contribute to Alzheimer's processes in this group, but as an observational study it does not test any treatment or prevention.
Study details
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 30 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 28 of the 94 points we could judge it on, which is 30 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 10 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.0 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Adam M. Brickman: h-index 87 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 14 institution(s) in 3 countries |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 28 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 28 of the 94 points we could judge it on is 30 out of 100. |
| Total | 30 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 23.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Down syndrome and Alzheimer's
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.